Whole Genome Analysis Informs Breast Cancer Response to Aromatase Inhibition

To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy by massively parallel sequencing and analysis. Eighteen significantly mutated genes were identified, including five genes (RUNX1, CBFB, MYH9, MLL3 and SF3B1) previously linked to haematopoietic disorders. Mutant MAP3K1 was associated with luminal A status, low-grade histology and low proliferation rates, whereas mutant TP53 was associated with the opposite pattern. Moreover, mutant GATA3 correlated with suppression of proliferation upon aromatase inhibitor treatment. Pathway analysis demonstrated that mutations in MAP2K4, a MAP3K1 substrate, produced similar perturbations as MAP3K1 loss. Distinct phenotypes in oestrogen-receptor-positive breast cancer are associated with specific patterns of somatic mutations that map into cellular pathways linked to tumour biology, but most recurrent mutations are relatively infrequent. Prospective clinical trials based on these findings will require comprehensive genome sequencing.

• Publication year

  2012

• Venue

  Nature

• Publication date

  2012-04-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nature11143PMID 22722193PMCID 3383766
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• POSTER PRESENTATION Open Access

  2013cited by this paper
• SomaticSniper: identification of somatic point mutations in whole genome sequencing data

  2012cited by this paper
• MuSiC: Identifying mutational significance in cancer genomes

  2012cited by this paper
• Antifibrotic effect of tamoxifen in a model of progressive renal disease.

  2012cited by this paper
• High-resolution characterization of a hepatocellular carcinoma genome

  2011cited by this paper
• Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts.

  2011cited by this paper
• SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

  2011cited by this paper
• PathScan: a tool for discerning mutational significance in groups of putative cancer genes

  2011cited by this paper
• MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis.

  2011cited by this paper
• Phosphorylation of SCG10/stathmin-2 determines multipolar stage exit and neuronal migration rate

  2011cited by this paper
• Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.

  2011cited by this paper
• Somatic Mutations of the Mixed-Lineage Leukemia 3 (MLL3) Gene in Primary Breast Cancers

  2011cited by this paper
• Diverse somatic mutation patterns and pathway alterations in human cancers.

  2010cited by this paper
• Genome-Wide Analysis of Estrogen Receptor α DNA Binding and Tethering Mechanisms Identifies Runx1 as a Novel Tethering Factor in Receptor-Mediated Transcriptional Activation

  2010cited by this paper
• A comprehensive catalogue of somatic mutations from a human cancer genome

  2010cited by this paper
• Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM

  2010cited by this paper
• Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling

  2010cited by this paper
• The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation.

  2010cited by this paper
• Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool

  2010cited by this paper
• The mutation spectrum revealed by paired genome sequences from a lung cancer patient

  2010cited by this paper
• Recurring mutations found by sequencing an acute myeloid leukemia genome.

  2009cited by this paper
• Circos: an information aesthetic for comparative genomics.

  2009cited by this paper
• Mammary development meets cancer genomics

  2009cited by this paper
• A small cell lung cancer genome reports complex tobacco exposure signatures

  2009cited by this paper
• Signal integration by JNK and p38 MAPK pathways in cancer development

  2009cited by this paper
• BreakDancer: An algorithm for high resolution mapping of genomic structural variation

  2009cited by this paper
• Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial.

  2009cited by this paper
• Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer

  2009cited by this paper
• Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics

  2008cited by this paper
• DNA sequencing of a cytogenetically normal acute myeloid leukemia genome

  2008cited by this paper
• The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway.

  2007cited by this paper
• DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation

  2007cited by this paper
• JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length

  2006cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• High Frequency of Mutations of the PIK3CA Gene in Human Cancers

  2004cited by this paper
• Mutation of GATA3 in human breast tumors

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Molecular mechanisms of autosomal recessive hypercholesterolemia

  2003cited by this paper
• Non‐muscle myosin heavy chain (MYH9): A new partner fused to ALK in anaplastic large cell lymphoma

  2003cited by this paper
• Mitogen-Activated Protein Kinase Pathways Mediated by ERK, JNK, and p38 Protein Kinases

  2002cited by this paper
• Molecular mechanisms of autosomal recessive hypercholesterolemia.

  2002cited by this paper
• Functional and Physical Interactions between AML1 Proteins and an ETS Protein, MEF: Implications for the Pathogenesis of t(8;21)-Positive Leukemias

  1999cited by this paper
• Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1

  1997cited by this paper
• MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42

  1997cited by this paper
• p27/Kip1 mutation found in breast cancer.

  1996cited by this paper
• E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.

  1995cited by this paper
• Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours.

  1990cited by this paper
• Structural rearrangement of the retinoblastoma gene in human breast carcinoma.

  1988cited by this paper

• Breast cancer inequities: the intersectional role of social epidemiology and tumor biology.

  2026cites this paper
• Unlocking the undruggable spliceosome: generative AI and structural dynamics in cancer therapy

  2026cites this paper
• Evaluating progesterone receptor agonist megestrol plus letrozole for women with early-stage estrogen-receptor-positive breast cancer: the window-of-opportunity, randomized, phase 2b, PIONEER trial

  2026influential citation
• DeepGene-BC: Deep Learning-Based Breast Cancer Subtype Prediction via Somatic Point Mutation Profiles.

  2026cites this paper
• The Future of Breast Cancer Treatment: From Conventional Wisdom to Nanotechnology-Enabled Precision

  2026cites this paper
• Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers

  2026cites this paper
• Exome sequencing of Hodgkin and non-Hodgkin composite lymphomas identifies shared somatic mutations indicative of common founding precursors.

  2026cites this paper
• Computational Characterization of MAP2K3 Mutations in Breast Cancer: Implications for Targeted Therapy Design

  2026cites this paper
• Biomarkers of response to neoadjuvant palbociclib plus anastrozole in endocrine-resistant estrogen receptor-positive/HER2-negative breast cancer: a phase 2 trial

  2026influential citation
• Micro-RNAs targeting the estrogen receptor alpha involved in endocrine therapy resistance in breast cancer.

  2025cites this paper
• A common structural mechanism for RNA recognition by the SF3B complex in mRNA splicing and export

  2025cites this paper
• p27Kip1 and Tumors: Characterization of CDKN1B Variants Identified in MEN4 and Breast Cancer

  2025cites this paper
• Discovery of epigenetically silenced tumour suppressor genes in aggressive breast cancer through a computational approach

  2025cites this paper
• Breast Cancer Risk and Management in the Endocrine Clinic: A Comprehensive Review.

  2025cites this paper
• Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer

  2025cites this paper
• SF3B1 mutations in spliceosome-driven tumorigenesis: From splicing dysregulation to signaling network rewiring and therapeutic targeting.

  2025cites this paper
• Magnetic chromatography improves colloidal and MRI attributes of magnetoliposomes enabling evaluation of the impact of size on bio-distribution in an in vivo model of pancreatic cancer.

  2025cites this paper
• Advances in breast cancer therapy: "Exploring the therapeutic potential of CDK 4/6 inhibitors and their clinical impact."

  2025cites this paper
• Genomic landscape of estrogen receptor-positive HER2-negative advanced breast cancer with acquired resistance to aromatase inhibitors: Identification of an ESR1 alteration-related gene signature

  2025cites this paper
• Navigating Endocrine Sensitivity Assessment in Nonmetastatic Breast Cancer Through Early On-Treatment Ki67 Understanding.

  2025cites this paper
• Anti-CSF-1R therapy with combined immuno- chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched Triple Negative Breast Cancers

  2025cites this paper
• Molecular heterogeneity and MYC dysregulation in triple-negative breast cancer: genomic advances and therapeutic implications

  2025cites this paper
• Comprehensive germline and somatic profiling of high-risk Thai breast cancer via next-generation sequencing

  2025cites this paper
• MAP3K1/MAP2K4 mutations drive breast cancer progression by compensating for TP53 loss through inactivation of the JNK2-p53-FOSL1 axis

  2025cites this paper
• A predictive endocrine resistance index accurately stratifies luminal breast cancer treatment responders and nonresponders

  2025cites this paper
• Clonal selection supported by single cell Dna sequencing reveals hormonal adaptation and resistance in locally advanced breast cancer During Neoadjuvant Aromatase Inhibition

  2025influential citation
• BCL-XL Protects ASS1-Deficient Cancers from Arginine Starvation–Induced Apoptosis

  2025cites this paper
• Triad-LMF: A Hierarchical Low-Rank Multimodal Fusion Framework for Robust Cancer Subtype Classification Using Multi-Omics Data

  2025cites this paper
• SF3B1: from core splicing factor to oncogenic driver

  2025cites this paper
• Key decision factors in second-line therapy: Expert insights on HR+/HER2-metastatic breast cancer post-CDK4/6 inhibitor progression.

  2025cites this paper
• Next-generation sequencing in cancer diagnosis and treatment: clinical applications and future directions

  2025cites this paper
• Landscape of metabolic alterations and treatment strategies in breast cancer

  2025cites this paper
• Kinesin-like protein KIFC2 stabilizes CDK4 to accelerate growth and confer resistance in HR+/HER2– breast cancer

  2025cites this paper
• GATA3 differentially regulates the transcriptome via zinc finger 2-modulated phase separation.

  2025cites this paper
• Genomic and proteomic profiling of GATA3 mutant metastatic hormone receptor-positive breast cancer and impact on clinical outcomes

  2025cites this paper
• Rat somatic genome editing enables ER+ breast cancer modeling

  2025cites this paper
• FLT3LG as an inflammatory hub bridging tumor immune surveillance to therapy response in breast cancer

  2025cites this paper
• Increased RUNX1 mutations in breast cancer disease progression.

  2024cites this paper
• PARP inhibition leads to synthetic lethality with key splicing-factor mutations in myelodysplastic syndromes

  2024cites this paper
• RUNX3 inhibits KSHV lytic replication by binding to the viral genome and repressing transcription

  2024cites this paper
• Rational correction of pathogenic conformational defects in HTRA1

  2024cites this paper
• The intersection of the HER2-low subtype with endocrine resistance: the role of interconnected signaling pathways

  2024cites this paper
• Structural screening and molecular simulation identify potential ligands against the K700E hot spot variant and functional pockets of SF3B1 to modulate splicing in myelodysplastic syndrome

  2024cites this paper
• Targeted Therapies in Cancer Treatment: Unveiling the Latest Breakthroughs and Promising Approaches

  2024cites this paper
• Single-cell omics: experimental workflow, data analyses and applications

  2024cites this paper
• The Dual Role of LncRNAs in Hepatocellular Carcinoma: Friend and Foe

  2024cites this paper
• Biomarkers for Oral Squamous Cell Carcinoma (miR-24, miR-200, and miR-34): Screening and Detection MicroRNA

  2024cites this paper
• Breast cancer genomic analyses reveal genes, mutations, and signaling networks

  2024cites this paper
• The modification role and tumor association with a methyltransferase: KMT2C

  2024cites this paper
• Aberrant p53 immunostaining patterns in breast carcinoma of no special type strongly correlate with presence and type of TP53 mutations

  2024cites this paper
• Proteogenomic analysis dissects early-onset breast cancer patients with prognostic relevance

  2024cites this paper
• Comprehensive Review of Breast Cancer for Precision Oncology

  2024cites this paper
• Aberrant pre-mRNA processing in cancer

  2024influential citation
• Mutational landscape of inflammatory breast cancer

  2024cites this paper
• Regulation of Pre-mRNA Splicing: Indispensable Role of Post-Translational Modifications of Splicing Factors

  2023cites this paper
• The Q-IMPROvE (Queensland-IMplementation of PRecision Oncology in brEast cancer) pilot study.

  2023cites this paper
• Studying the connection between SF3B1 and four types of cancer by analyzing networks constructed based on published research

  2023cites this paper
• Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.

  2023cites this paper
• RUNX3 in Stem Cell and Cancer Biology

  2023cites this paper
• Discovery of Transacting Long Noncoding RNAs That Regulate Smooth Muscle Cell Phenotype

  2023cites this paper
• The RUNX/CBFβ Complex in Breast Cancer: A Conundrum of Context

  2023cites this paper
• Genetics, Treatment, and New Technologies of Hormone Receptor-Positive Breast Cancer

  2023cites this paper
• Pathogenic role of 25-hydroxycholesterol in cancer development and progression.

  2023cites this paper
• HER2-driven breast cancer suppression by the JNK signaling pathway

  2023cites this paper
• Reduction of daily-use parabens and phthalates reverses accumulation of cancer-associated phenotypes within disease-free breast tissue of study subjects.

  2023cites this paper
• p53 Expression in Luminal Breast Cancer Correlates With TP53 Mutation and Primary Endocrine Resistance.

  2023cites this paper
• Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions

  2023cites this paper
• Characterization of the SF3B1–SUGP1 interface reveals how numerous cancer mutations cause mRNA missplicing

  2023cites this paper
• Association of Germline Variation in Driver Genes with Breast Cancer Risk in Chilean Population

  2023cites this paper
• The role of alternative pre-mRNA splicing in cancer progression

  2023cites this paper
• Current Status of Next-Generation Sequencing in Bone Genetic Diseases

  2023cites this paper
• ESR1 Gene Mutations and Liquid Biopsy in ER-Positive Breast Cancers: A Small Step Forward, a Giant Leap for Personalization of Endocrine Therapy?

  2023cites this paper
• Distinct shared and compartment-enriched oncogenic networks drive primary versus metastatic breast cancer

  2023cites this paper
• MALAT1 Long Non-coding RNA and Its Role in Breast Carcinogenesis

  2023cites this paper
• Breast cancers with high proliferation and low ER-related signalling have poor prognosis and unique molecular features with implications for therapy

  2023cites this paper
• Whole Exome Sequencing of Thymoma Patients Exhibiting Exceptional Responses to Pemetrexed Monotherapy

  2023cites this paper
• Identification of Liver Cancer Driver Mutations from COSMIC Data

  2023cites this paper
• Timed hazard networks: Incorporating temporal difference for oncogenetic analysis

  2023cites this paper
• Deciphering breast cancer: from biology to the clinic.

  2023cites this paper
• Analysis of super-enhancer using machine learning and its application to medical biology

  2023cites this paper
• The Metastatic Breast Cancer Project: leveraging patient-partnered research to expand the clinical and genomic landscape of metastatic breast cancer and accelerate discoveries

  2023cites this paper
• Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors

  2023cites this paper
• Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment

  2023cites this paper
• Frequency of genetic alterations differs in advanced breast cancer between metastatic sites

  2023cites this paper
• LncRNA MALAT1 signaling pathway and clinical applications in overcome on cancers metastasis

  2023cites this paper
• TMEM97 Expression Level Related to Tamoxifen Resistance in Breast Cancer Cells

  2023cites this paper
• Editing of the MALAT1 Gene in MDA-MB-361 Breast Cancer Cell Line using the Novel CRISPR Method

  2022cites this paper
• Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance

  2022cites this paper
• Microfluidic Strategies for Extracellular Vesicle Isolation: Towards Clinical Applications

  2022cites this paper
• DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer

  2022cites this paper
• Insights into the role of RUNX1 gene in female-related cancers

  2022cites this paper
• Diabetic Retinopathy: Are lncRNAs New Molecular Players and Targets?

  2022cites this paper
• Genomic Profiling and Liquid Biopsies for Breast Cancer.

  2022cites this paper
• Endocrine resistance and breast cancer plasticity are controlled by CoREST

  2022cites this paper
• RUNX Proteins as Epigenetic Modulators in Cancer

  2022cites this paper
• Harnessing gene fusion-derived neoantigens for 'cold' breast and prostate tumor immunotherapy.

  2022cites this paper
• COL3A1: Potential prognostic predictor for head and neck cancer based on immune‐microenvironment alternative splicing

  2022cites this paper
• Whole Exome and Whole Genome Sequencing

  2022cites this paper
• The role of SF3B1 and NOTCH1 in the pathogenesis of leukemia

  2022cites this paper
• KMT2C-deficient tumors have elevated APOBEC mutagenesis and genomic instability in multiple cancers

  2022cites this paper